Public Comments
Comments provided on: July 20, 2020
Comments provided to: Food and Drug Administration (FDA)
Resource Type: Public Comments
Response to FDA’s request for comments on strategic priorities for the Office of Minority Health and Health Equity (OMHHE)
Public Comments
Comments provided on: June 29, 2020
Comments provided to: Food and Drug Administration (FDA)
Response to European Commission’s request for feedback regarding the General Data Protection Regulation (GDPR)
Public Comments
Comments provided on: April 29, 2020
Comments provided to : European Commission
Comments to EDPB on the Guidelines on the Territorial Scope of the GDPR
Public Comments
Comments provided on: January 18, 2019
Comments provided to: European Data Protection Board
Regulation of New Drugs and Clinical Trials Rules: Comments and Recommendations
Public Comments
Comments provided on: March 16, 2018
Comments provided to: Ministry of Health and Family Welfare, New Delhi, India
NIH and FDA Draft Clinical Trial Protocol Template for Phase 2 and 3 IND/IDE Studies
Public Comments
Comments Provided on: April 15, 2016
Comments Provided to: The International Committee of Medical Journal Editors
Scientific Data – Editorial Comments
Public Comments
Comments provided on: September 7, 2015
Comments provided to: Scientific Data
Comments provided by: MRCT Center Data Sharing and Transparency workgroup
Comments to China FDA on resolving the backlog
Public Comments
Comments provided on: August 11, 2015
Comments: China Food and Drug Administration, Beijing, China
Comments to China FDA on resolving the backlog, Chinese Translation
Public Comments
Comments provided on: August 11, 2015
Comments provided to: China Food and Drug Administration, Beijing, China
Drugs and Cosmetics Amendment Bill Comments and Recommendations
Public Comments
Comments provided on: January 11, 2015
Comments provided to: Department of Health and Family Welfare, New Delhi, India